Alnylam Pharmaceuticals · 1 day ago
Senior Scientist, Statistical Genetics
Cambridge, MA
Full-time
Onsite
Mid, Senior Level
$127K/yr - $180K/yr
3+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, dedicated to transforming the lives of individuals with rare and common diseases. They are seeking a passionate scientist to apply human genetics to drug discovery and development, focusing on uncovering new therapeutic targets through comprehensive analyses of human genetic data.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Hiring Manager
Jeannine Ripley
Responsibilities
Apply human genetics (common and rare genetic association studies) using biobank-scale data (e.g., UK Biobank, All of Us, Our Future Health, Alliance for Genomic Discovery) with the aim of finding new targets for RNAi therapeutics
Perform biobank-scale association analyses, conduct meta-analyses across diverse cohorts, including leveraging publicly available summary statistics, and integrate findings with molecular QTLs and other omics data to strength hypotheses
Perform post-GWAS analyses aimed at identifying causal genes and potential therapeutic targets (e.g., fine-mapping, colocalization, Mendelian Randomization)
Lead target finding and validation efforts in at least one therapeutic area of interest to Alnylam (e.g., metabolic disease, cardiovascular disease, neurological disorders, rare disease)
Collaborate closely with cross-functional teams to follow-up on promising targets and to deliver genetic analyses that will help inform existing drug development programs
Stay at the forefront of statistical and computational genetics methods, implementing innovative approaches that accelerate target discovery and validation
Communicate findings effectively through internal presentations, project reports, and/or high-impact publications
Qualification
Required
PhD in Statistical Genetics or a related field
3+ years of relevant post-graduate experience applying genetics to drug target discovery
Demonstrated expertise in GWAS and/or RVAS, meta-analysis, and performing post-GWAS analyses to help elucidate causal mechanisms (e.g. fine-mapping, colocalization, TWAS, Mendelian Randomization, polygenic risk prediction)
Track record using genetic data to make novel biological insights or find new drug targets
Deep knowledge of at least one therapeutic area (e.g., metabolic disease, cardiovascular disease, neurological disorders, rare disease) with the ability to contextualize genetics findings into biological mechanisms and clinical relevance
Demonstrated experience collaborating with biologists, disease area experts, and physician scientists to interpret the results of genetic analyses, support disease understanding and prioritize follow-up work
Well-versed in leveraging publicly available genetics resources e.g., OpenTargets, OMIM, GTEx, GWAS catalog
Proficiency with statistical genetics tools (e.g., PLINK, REGENIE, SKAT, etc.) and strong hands-on skills in R and Linux command line
Experience working in cloud computational environments for genomics such as the (e.g., UKB RAP, All of Us Researcher Workbench, ICA)
Independent, detail-orientated scientist with excellent communication skills and a record of publishing impactful research
Benefits
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
H1B Sponsorship
Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
2025-12-22
2025-12-20
Company data provided by crunchbase